Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Depreciation & Amortization (CF) (2019 - 2025)

Revolution Medicines (RVMD) has 7 years of Depreciation & Amortization (CF) data on record, last reported at $2.3 million in Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 30.66% year-over-year to $2.3 million; the TTM value through Dec 2025 reached $7.8 million, up 18.62%, while the annual FY2025 figure was $7.8 million, 18.62% up from the prior year.
  • Depreciation & Amortization (CF) reached $2.3 million in Q4 2025 per RVMD's latest filing, up from $2.1 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $2.3 million in Q4 2025 and bottomed at $671000.0 in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $1.3 million, with a median of $1.3 million recorded in 2023.
  • Peak YoY movement for Depreciation & Amortization (CF): rose 6.17% in 2021, then soared 37.94% in 2022.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $833000.0 in 2021, then skyrocketed by 37.94% to $1.1 million in 2022, then grew by 13.14% to $1.3 million in 2023, then soared by 33.46% to $1.7 million in 2024, then soared by 30.66% to $2.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $2.3 million in Q4 2025, $2.1 million in Q3 2025, and $1.8 million in Q2 2025.